MedImmune, a subsidiary of AstraZeneca PLC, and Celgene are collaborating on a programme to develop and commercialise an anti-PD-L1 inhibitor, MEDI4736, for the treatment of myeloma and other haematological malignancies. MEDI4736 is a human anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody which works as an immune checkpoint inhibitor and enables the immune system to continue to attack cancer cells. The collaboration will seek to explore the clinical potential of combining different immunotherapies as possible treatment strategies for blood cancers, including myeloma.

Read full article